申请人:Knoll Atkiengesellschaft
公开号:US05767116A1
公开(公告)日:1998-06-16
Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof in which A is methylene or --O--; B is methylene or --O--; and g is 0, 1, 2, 3 or 4; R.sub.1, R.sub.2, R.sub.3, R.sub.4, U, Q and T are defined in claim 1. The compounds have utility in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, and spasticity.
化合物I的结构如下,并且其药学上可接受的盐,其中A为亚甲基或--O--; B为亚甲基或--O--; g为0、1、2、3或4; R.sub.1、R.sub.2、R.sub.3、R.sub.4、U、Q和T的定义如索赔1所述。这些化合物在治疗中枢神经系统疾病方面具有用途,例如抑郁症、焦虑症、精神病(例如精神分裂症)、迟发性运动障碍、帕金森病、肥胖症、高血压、杜雷特综合征、性功能障碍、药物成瘾、药物滥用、认知障碍、阿尔茨海默病、老年性痴呆、强迫行为、惊恐发作、进食障碍和厌食症、心血管和脑血管疾病、非胰岛素依赖型糖尿病、高血糖、便秘、心律失常、神经内分泌系统疾病、压力、前列腺肥大和痉挛症。